This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia (CL)

This study has been completed.
Information provided by:
Emory University Identifier:
First received: December 3, 2007
Last updated: September 1, 2010
Last verified: July 2009
Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.

Condition Intervention Phase
Progressive Keratoconus Corneal Ectasia Procedure: Corneal collagen Procedure: Sham comparator Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia or Progressive Keratoconus

Resource links provided by NLM:

Further study details as provided by Emory University:

Primary Outcome Measures:
  • Change in keratometry [ Time Frame: 3 Months ]

Secondary Outcome Measures:
  • Best spectacle-corrected visual acuity [ Time Frame: 3 Months ]

Estimated Enrollment: 160
Study Start Date: December 2007
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Corneal collagen cross-linking
Procedure: Corneal collagen
Corneal collagen cross-linking with riboflavin/UVA light
Sham Comparator: Control
Sham Treatment
Procedure: Sham comparator
Sham treatment

Detailed Description:

Subjects are randomized to a control group or a treatment group, with the control group crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is performed as a single treatment. Subjects are followed for at least 12 months to evaluate the long term effects of corneal collagen cross-linking.

Subjects may be referred from other physicians but must return to Emory Vision for completion of all study visits.


Ages Eligible for Study:   14 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of keratoconus with documented progression over the previous 12 months.
  • Diagnosis of corneal ectasia
  • Must be able to complete all study visits

Exclusion Criteria:

  • Prior corneal surgery in the keratoconus group
  • Corneal scarring
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00567671

United States, Georgia
Woolfson Eye Institute
Atlanta, Georgia, United States, 30328
Sponsors and Collaborators
Emory University
Principal Investigator: R. Doyle Stulting, MD, PhD Emory Vision; Emory University
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: R. Doyle Stulting, MD, PhD., Professor of Ophthalmology, Emeritus, Principle Investigator, Woolfson Eye Intitute Identifier: NCT00567671     History of Changes
Other Study ID Numbers: UVX-001
Study First Received: December 3, 2007
Last Updated: September 1, 2010

Keywords provided by Emory University:
UVA light

Additional relevant MeSH terms:
Dilatation, Pathologic
Corneal Diseases
Eye Diseases
Pathological Conditions, Anatomical processed this record on June 23, 2017